News for Zogenix, Inc. (ZGNX)

PR NewswireATLANTA, Feb. 27, 2025 Revenue in 2024 increased to € 6.15 billion, a plus of 17% (+19% CER1),Net sales were up by 15% to € 5.61 billion (+1

**media[548579]**

Operator: Good morning or good afternoon and welcome to the Ermenegildo Zegna Group FY 2023 Financial Results Call. My name is Arden and I will be your operator today.

NEWS RELEASE March 26, 2024 UCB Japan Obtained Additional Application of Fintepla® for the Treatment of Seizures...

The schizophrenia market is expected to grow significantly owing to an increase in the patient pool due to changes in lifestyle, an increase in the...

The dynamics of the Lennox-Gastaut syndrome market are anticipated to change in the coming years owing to the expected launch of emerging therapies during...

Ovid Therapeutics' TAK-935 has a high potential for positive Phase 3 clinical trial results for Dravet Syndrome and Lennox-Gastaut Syndrome. Find out why OVID stock is a Buy.

/PRNewswire/ -- UCB (Euronext: UCB), a global biopharmaceutical company, today announced the U.S. Drug Enforcement Administration (DEA) has published a final...

Operator: Hello, everyone, and welcome to the Ermenegildo Zegna Group Full Year 2022 Results. My name is Bruno, and I'll be the operator of today. .

/PRNewswire/ -- DelveInsight's 'Schizophrenia Pipeline Insight – 2023' report provides comprehensive global coverage of available, marketed, and pipeline...

/PRNewswire/ -- The "Dravet Syndrome Market Share, Size, Trends, Industry Analysis Report, By Type of Seizures; By Diagnosis; By Severity; By Treatment; By...

Cerevel promised multiple data readouts in 2022 and 2023 but the major ones are now delayed until 2024.

/PRNewswire/ -- The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around...

Acumen Research and Consulting recently published report titled “Needle-Free Injection Market and Region Forecast, 2022 - 2030”...

In the following guest post, the authors revisit the question of whether or not securities class action lawsuits against development-stage biotech

/PRNewswire/ -- The

GuruFocus Article or News written by GuruFocusNews and the topic is about:

WILMINGTON, Del., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating Zogenix, Inc. (“Zogenix”) (NASDAQ GM: ZGNX)...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Au...